Changing Prevalence and Antibiotic Drug Resistance Pattern of Pathogens Seen in Community-acquired Pediatric Urinary Tract Infections at a Tertiary Care Hospital of North India
Overview
Affiliations
Aims And Objectives: The aim and objective of this study was to assess the temporal changes in the microbiological profiles and antimicrobial resistance patterns of uropathogens in pediatric community-acquired UTI.
Materials And Methods: This is a retrospective analysis of data collected over a Scattered period of 5 years. The baseline data collected were from January to December 2009, and the second period considered for comparison was from January to December 2014. Urine specimens from children (<17 years) suspected of UTI were cultured by a semi-quantitative method on cysteine lactose electrolyte-deficient medium. Antibiotic sensitivity was put up by Kirby-Bauer disc diffusion method as per the Clinical and Laboratory Standard Institute guidelines.
Results: In the year 2009, 340 of 2104 (16.15%) urine specimens yielded significant colony count, whereas in 2014, it was 407 of 2212 (18.39%) ( = 0.051). was the predominant pathogen and was significantly more prevalent in girls than in boys ( < 0.0001) during both periods. There was a significant overall increase in resistance to ampicillin (from 40.29% to 58.72%), amoxyclav (from 26.17% to 40.54%), nitrofurantoin (from 28.82% to 39.06%), and norfloxacin (from 30% to 41.42%). However, the maximum increase in the resistance was noted for co-trimoxazole from 35.58% in 2009 to 63.39% in 2014 ( = 0.0000058). The prevalence of extended-spectrum beta-lactamases (ESBLs) has also significantly increased from 21.7% to 33.16% ( = 0.0045).
Conclusion: Although remains the prime pathogen in pediatric UTI, the prevalence of resistance has dramatically increased over the 5-year study period. Our study highlights the emergence of community-acquired ESBL-producing uropathogens in children proclaiming treatment challenges.
Tahmasebi H, Arjmand N, Monemi M, Babaeizad A, Alibabaei F, Alibabaei N Biomolecules. 2025; 15(1).
PMID: 39858487 PMC: 11764262. DOI: 10.3390/biom15010093.
Hogea E, Muntean A, Bratosin F, Bogdan I, Plavitu O, Fratutu A Antibiotics (Basel). 2024; 13(6).
PMID: 38927179 PMC: 11201005. DOI: 10.3390/antibiotics13060512.
Contemporary Management of Urinary Tract Infections in Children.
Olson P, Dudley A, Rowe C Curr Treat Options Pediatr. 2023; 8(3):192-210.
PMID: 37521173 PMC: 9108690. DOI: 10.1007/s40746-022-00242-1.
Mohapatra S, Ghosh D, Vivekanandan P, Chunchanur S, Venugopal S, Tak V Antimicrob Resist Infect Control. 2023; 12(1):36.
PMID: 37072773 PMC: 10114455. DOI: 10.1186/s13756-023-01233-z.
Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections.
Veeraraghavan B, Bakthavatchalam Y, Sahni R Infect Dis Ther. 2021; 10(4):1815-1835.
PMID: 34357517 PMC: 8572892. DOI: 10.1007/s40121-021-00509-4.